← Back to Clinical Trials
Recruiting NCT06628570

NCT06628570 Screening Strategies Among High-risk Populations for Anal Cancer

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06628570
Status Recruiting
Phase
Sponsor Lisa Flowers
Condition Neoplasms
Study Type INTERVENTIONAL
Enrollment 500 participants
Start Date 2024-12-16
Primary Completion 2027-09-30

Eligibility & Interventions

Sex All sexes
Min Age 30 Years
Max Age 80 Years
Study Type INTERVENTIONAL
Interventions
HRA + BiopsyAnal CytologyGenotyping of anal hrHPV infection

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 500 participants in total. It began in 2024-12-16 with a primary completion date of 2027-09-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of the proposed research is to 1) examine the performance of emerging screening methods for anal high-grade squamous intraepithelial lesion (aHSIL), a precancerous condition of anal cancer, among populations at high risk for anal cancer and 2) characterize DNA methylation, immunologic response, and environmental factors associated with aHSIL.

Eligibility Criteria

Inclusion Criteria: * 30-80 years of age * Individuals with chronic impaired immune status * History of lower genital tract neoplasia (LGTN), Zubrod Performance Status of 0-2 Exclusion Criteria: * Patients treated for aHSIL less than 6 months before screening * History of anal cancer and pregnant women.

Contact & Investigator

Central Contact

Lisa Flowers, MD, MPH

✉ lflowe2@emory.edu

📞 404-251-8931

Principal Investigator

Lisa Flowers, MD, MPH

PRINCIPAL INVESTIGATOR

Emory University

Frequently Asked Questions

Who can join the NCT06628570 clinical trial?

This trial is open to participants of all sexes, aged 30 Years or older, up to 80 Years, studying Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06628570 currently recruiting?

Yes, NCT06628570 is actively recruiting participants. Contact the research team at lflowe2@emory.edu for enrollment information.

Where is the NCT06628570 trial being conducted?

This trial is being conducted at Miami, United States, Miami, United States, Atlanta, United States, Atlanta, United States.

Who is sponsoring the NCT06628570 clinical trial?

NCT06628570 is sponsored by Lisa Flowers. The principal investigator is Lisa Flowers, MD, MPH at Emory University. The trial plans to enroll 500 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology